Ductal carcinoma in situ of the breast: immune cell composition according to subtype
Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response...
Gespeichert in:
| Veröffentlicht in: | Modern pathology 2020-02, Vol.33 (2), p.196-205 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 205 |
|---|---|
| container_issue | 2 |
| container_start_page | 196 |
| container_title | Modern pathology |
| container_volume | 33 |
| creator | Agahozo, Marie Colombe van Bockstal, Mieke R. Groenendijk, Floris H. van den Bosch, Thierry P. P. Westenend, Pieter J. van Deurzen, Carolien H. M. |
| description | Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response by characterizing immune cell subsets according to ductal carcinoma in situ subtypes. Ductal carcinoma in situ-associated tumor infiltrating lymphocyte (TIL) density was evaluated based on hematoxylin and eosin (H&E)-stained sections from 473 patients. Cases were subtyped based on ER, PR, and HER2. Patients were categorized as TIL-high or low. Ductal carcinoma in situ-associated immune cells of TIL-high cases were immunostained on whole slides with CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 and SP263). In total, 131/473 patients (28.0%) were considered as TIL-high. The percentage of TIL-high cases was significantly higher in HER2+ and triple-negative ductal carcinoma in situ (
P
|
| doi_str_mv | 10.1038/s41379-019-0331-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2268312552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475023446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-2c6b0fd96dee7a4e98e41b682abf93c803cf775a75006dbf5ab490dd25c799533</originalsourceid><addsrcrecordid>eNp9kTtPwzAUhS0EoqXwA1iQJRaWgJ-JzYbKU6rEUmbLcZySqomL7Qz99zhKAQkJhqs73O-cc6UDwDlG1xhRcRMYpoXMEE5DKc7EAZhiTlGGiOCHYIqEpBmVnEzASQhrhDDjghyDCU06XuRsCpb3vYl6A432pulcq2HTwdDEHroaxncLS291iLewadu-s9DYTYJdu3UJalwHtTHOV023gtHB0Jdxt7Wn4KjWm2DP9nsG3h4flvPnbPH69DK_W2SGMRozYvIS1ZXMK2sLzawUluEyF0SXtaRGIGrqouC64AjlVVlzXTKJqopwU0jJKZ2Bq9F3691Hb0NUbROGD3VnXR8UIbmgmHBOEnr5C1273nfpO0VYCiCUsfxfijKJC5bLIRaPlPEuBG9rtfVNq_1OYaSGYtRYjErFqKEYJZLmYu_cl62tvhVfTSSAjEBIp25l_U_0366fg7SXSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2349174693</pqid></control><display><type>article</type><title>Ductal carcinoma in situ of the breast: immune cell composition according to subtype</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Agahozo, Marie Colombe ; van Bockstal, Mieke R. ; Groenendijk, Floris H. ; van den Bosch, Thierry P. P. ; Westenend, Pieter J. ; van Deurzen, Carolien H. M.</creator><creatorcontrib>Agahozo, Marie Colombe ; van Bockstal, Mieke R. ; Groenendijk, Floris H. ; van den Bosch, Thierry P. P. ; Westenend, Pieter J. ; van Deurzen, Carolien H. M.</creatorcontrib><description>Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response by characterizing immune cell subsets according to ductal carcinoma in situ subtypes. Ductal carcinoma in situ-associated tumor infiltrating lymphocyte (TIL) density was evaluated based on hematoxylin and eosin (H&E)-stained sections from 473 patients. Cases were subtyped based on ER, PR, and HER2. Patients were categorized as TIL-high or low. Ductal carcinoma in situ-associated immune cells of TIL-high cases were immunostained on whole slides with CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 and SP263). In total, 131/473 patients (28.0%) were considered as TIL-high. The percentage of TIL-high cases was significantly higher in HER2+ and triple-negative ductal carcinoma in situ (
P
< 0.0001). Overall, no statistical difference in immune cell composition according to subtypes was found. However, individual subtype comparison showed that ER+ HER2+ cases had a significantly higher proportion of CD8+ T cells compared with triple-negative cases (
P
= 0.047). In TIL-high cases, PD-L1-SP142 expression on tumor cells was associated with subtype (
P
= 0.037); the lowest number of positive cases was observed in the HER2+ subtype (independent of ER). However, in TIL-high ductal carcinoma in situ, PD-L1 expression by both clones was limited. In conclusion, high numbers of TILs are predominantly observed in HER+ and triple negative ductal carcinoma in situ. The ER+ HER2+ subtype seems to attract a higher proportion of CD8+ T cells compared with the triple negative subtype. Among TIL-high cases, the HER2+ subgroup had the lowest PD-L1-SP142 expression on tumor cells. This suggests a more pronounced antitumor immunity in HER2+ ductal carcinoma in situ, which could play a role in its biological behavior.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/s41379-019-0331-8</identifier><identifier>PMID: 31375764</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>13/51 ; 631/67/1347 ; 631/67/580/1884 ; Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen - analysis ; Biomarkers, Tumor - analysis ; Breast ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - immunology ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Carcinoma, Intraductal, Noninfiltrating - chemistry ; Carcinoma, Intraductal, Noninfiltrating - immunology ; Carcinoma, Intraductal, Noninfiltrating - pathology ; Carcinoma, Intraductal, Noninfiltrating - therapy ; CD20 antigen ; CD4 antigen ; CD4-Positive T-Lymphocytes - immunology ; CD8 antigen ; CD8-Positive T-Lymphocytes - immunology ; ErbB-2 protein ; Female ; Foxp3 protein ; Health risk assessment ; Humans ; Immunophenotyping ; Laboratory Medicine ; Lymphocytes T ; Lymphocytes, Tumor-Infiltrating - immunology ; Medicine ; Medicine & Public Health ; Middle Aged ; Pathology ; PD-L1 protein ; Phenotype ; Prognosis ; Receptor, ErbB-2 - analysis ; Retrospective Studies ; Triple Negative Breast Neoplasms - chemistry ; Triple Negative Breast Neoplasms - immunology ; Triple Negative Breast Neoplasms - pathology ; Triple Negative Breast Neoplasms - therapy ; Tumor cells</subject><ispartof>Modern pathology, 2020-02, Vol.33 (2), p.196-205</ispartof><rights>United States & Canadian Academy of Pathology 2019</rights><rights>2019© United States & Canadian Academy of Pathology 2019</rights><rights>United States & Canadian Academy of Pathology 2019.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-2c6b0fd96dee7a4e98e41b682abf93c803cf775a75006dbf5ab490dd25c799533</citedby><cites>FETCH-LOGICAL-c443t-2c6b0fd96dee7a4e98e41b682abf93c803cf775a75006dbf5ab490dd25c799533</cites><orcidid>0000-0003-4498-928X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2349174693?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31375764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agahozo, Marie Colombe</creatorcontrib><creatorcontrib>van Bockstal, Mieke R.</creatorcontrib><creatorcontrib>Groenendijk, Floris H.</creatorcontrib><creatorcontrib>van den Bosch, Thierry P. P.</creatorcontrib><creatorcontrib>Westenend, Pieter J.</creatorcontrib><creatorcontrib>van Deurzen, Carolien H. M.</creatorcontrib><title>Ductal carcinoma in situ of the breast: immune cell composition according to subtype</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response by characterizing immune cell subsets according to ductal carcinoma in situ subtypes. Ductal carcinoma in situ-associated tumor infiltrating lymphocyte (TIL) density was evaluated based on hematoxylin and eosin (H&E)-stained sections from 473 patients. Cases were subtyped based on ER, PR, and HER2. Patients were categorized as TIL-high or low. Ductal carcinoma in situ-associated immune cells of TIL-high cases were immunostained on whole slides with CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 and SP263). In total, 131/473 patients (28.0%) were considered as TIL-high. The percentage of TIL-high cases was significantly higher in HER2+ and triple-negative ductal carcinoma in situ (
P
< 0.0001). Overall, no statistical difference in immune cell composition according to subtypes was found. However, individual subtype comparison showed that ER+ HER2+ cases had a significantly higher proportion of CD8+ T cells compared with triple-negative cases (
P
= 0.047). In TIL-high cases, PD-L1-SP142 expression on tumor cells was associated with subtype (
P
= 0.037); the lowest number of positive cases was observed in the HER2+ subtype (independent of ER). However, in TIL-high ductal carcinoma in situ, PD-L1 expression by both clones was limited. In conclusion, high numbers of TILs are predominantly observed in HER+ and triple negative ductal carcinoma in situ. The ER+ HER2+ subtype seems to attract a higher proportion of CD8+ T cells compared with the triple negative subtype. Among TIL-high cases, the HER2+ subgroup had the lowest PD-L1-SP142 expression on tumor cells. This suggests a more pronounced antitumor immunity in HER2+ ductal carcinoma in situ, which could play a role in its biological behavior.</description><subject>13/51</subject><subject>631/67/1347</subject><subject>631/67/580/1884</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>B7-H1 Antigen - analysis</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Breast</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Carcinoma, Intraductal, Noninfiltrating - chemistry</subject><subject>Carcinoma, Intraductal, Noninfiltrating - immunology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - pathology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - therapy</subject><subject>CD20 antigen</subject><subject>CD4 antigen</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Foxp3 protein</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>Laboratory Medicine</subject><subject>Lymphocytes T</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Pathology</subject><subject>PD-L1 protein</subject><subject>Phenotype</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Retrospective Studies</subject><subject>Triple Negative Breast Neoplasms - chemistry</subject><subject>Triple Negative Breast Neoplasms - immunology</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Triple Negative Breast Neoplasms - therapy</subject><subject>Tumor cells</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kTtPwzAUhS0EoqXwA1iQJRaWgJ-JzYbKU6rEUmbLcZySqomL7Qz99zhKAQkJhqs73O-cc6UDwDlG1xhRcRMYpoXMEE5DKc7EAZhiTlGGiOCHYIqEpBmVnEzASQhrhDDjghyDCU06XuRsCpb3vYl6A432pulcq2HTwdDEHroaxncLS291iLewadu-s9DYTYJdu3UJalwHtTHOV023gtHB0Jdxt7Wn4KjWm2DP9nsG3h4flvPnbPH69DK_W2SGMRozYvIS1ZXMK2sLzawUluEyF0SXtaRGIGrqouC64AjlVVlzXTKJqopwU0jJKZ2Bq9F3691Hb0NUbROGD3VnXR8UIbmgmHBOEnr5C1273nfpO0VYCiCUsfxfijKJC5bLIRaPlPEuBG9rtfVNq_1OYaSGYtRYjErFqKEYJZLmYu_cl62tvhVfTSSAjEBIp25l_U_0366fg7SXSg</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Agahozo, Marie Colombe</creator><creator>van Bockstal, Mieke R.</creator><creator>Groenendijk, Floris H.</creator><creator>van den Bosch, Thierry P. P.</creator><creator>Westenend, Pieter J.</creator><creator>van Deurzen, Carolien H. M.</creator><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4498-928X</orcidid></search><sort><creationdate>20200201</creationdate><title>Ductal carcinoma in situ of the breast: immune cell composition according to subtype</title><author>Agahozo, Marie Colombe ; van Bockstal, Mieke R. ; Groenendijk, Floris H. ; van den Bosch, Thierry P. P. ; Westenend, Pieter J. ; van Deurzen, Carolien H. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-2c6b0fd96dee7a4e98e41b682abf93c803cf775a75006dbf5ab490dd25c799533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>13/51</topic><topic>631/67/1347</topic><topic>631/67/580/1884</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>B7-H1 Antigen - analysis</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Breast</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Carcinoma, Intraductal, Noninfiltrating - chemistry</topic><topic>Carcinoma, Intraductal, Noninfiltrating - immunology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - pathology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - therapy</topic><topic>CD20 antigen</topic><topic>CD4 antigen</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Foxp3 protein</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>Laboratory Medicine</topic><topic>Lymphocytes T</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Pathology</topic><topic>PD-L1 protein</topic><topic>Phenotype</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Retrospective Studies</topic><topic>Triple Negative Breast Neoplasms - chemistry</topic><topic>Triple Negative Breast Neoplasms - immunology</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Triple Negative Breast Neoplasms - therapy</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agahozo, Marie Colombe</creatorcontrib><creatorcontrib>van Bockstal, Mieke R.</creatorcontrib><creatorcontrib>Groenendijk, Floris H.</creatorcontrib><creatorcontrib>van den Bosch, Thierry P. P.</creatorcontrib><creatorcontrib>Westenend, Pieter J.</creatorcontrib><creatorcontrib>van Deurzen, Carolien H. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agahozo, Marie Colombe</au><au>van Bockstal, Mieke R.</au><au>Groenendijk, Floris H.</au><au>van den Bosch, Thierry P. P.</au><au>Westenend, Pieter J.</au><au>van Deurzen, Carolien H. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ductal carcinoma in situ of the breast: immune cell composition according to subtype</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>33</volume><issue>2</issue><spage>196</spage><epage>205</epage><pages>196-205</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><abstract>Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response by characterizing immune cell subsets according to ductal carcinoma in situ subtypes. Ductal carcinoma in situ-associated tumor infiltrating lymphocyte (TIL) density was evaluated based on hematoxylin and eosin (H&E)-stained sections from 473 patients. Cases were subtyped based on ER, PR, and HER2. Patients were categorized as TIL-high or low. Ductal carcinoma in situ-associated immune cells of TIL-high cases were immunostained on whole slides with CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 and SP263). In total, 131/473 patients (28.0%) were considered as TIL-high. The percentage of TIL-high cases was significantly higher in HER2+ and triple-negative ductal carcinoma in situ (
P
< 0.0001). Overall, no statistical difference in immune cell composition according to subtypes was found. However, individual subtype comparison showed that ER+ HER2+ cases had a significantly higher proportion of CD8+ T cells compared with triple-negative cases (
P
= 0.047). In TIL-high cases, PD-L1-SP142 expression on tumor cells was associated with subtype (
P
= 0.037); the lowest number of positive cases was observed in the HER2+ subtype (independent of ER). However, in TIL-high ductal carcinoma in situ, PD-L1 expression by both clones was limited. In conclusion, high numbers of TILs are predominantly observed in HER+ and triple negative ductal carcinoma in situ. The ER+ HER2+ subtype seems to attract a higher proportion of CD8+ T cells compared with the triple negative subtype. Among TIL-high cases, the HER2+ subgroup had the lowest PD-L1-SP142 expression on tumor cells. This suggests a more pronounced antitumor immunity in HER2+ ductal carcinoma in situ, which could play a role in its biological behavior.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>31375764</pmid><doi>10.1038/s41379-019-0331-8</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-4498-928X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-3952 |
| ispartof | Modern pathology, 2020-02, Vol.33 (2), p.196-205 |
| issn | 0893-3952 1530-0285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2268312552 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | 13/51 631/67/1347 631/67/580/1884 Adult Aged Aged, 80 and over B7-H1 Antigen - analysis Biomarkers, Tumor - analysis Breast Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - immunology Breast Neoplasms - pathology Breast Neoplasms - therapy Carcinoma, Intraductal, Noninfiltrating - chemistry Carcinoma, Intraductal, Noninfiltrating - immunology Carcinoma, Intraductal, Noninfiltrating - pathology Carcinoma, Intraductal, Noninfiltrating - therapy CD20 antigen CD4 antigen CD4-Positive T-Lymphocytes - immunology CD8 antigen CD8-Positive T-Lymphocytes - immunology ErbB-2 protein Female Foxp3 protein Health risk assessment Humans Immunophenotyping Laboratory Medicine Lymphocytes T Lymphocytes, Tumor-Infiltrating - immunology Medicine Medicine & Public Health Middle Aged Pathology PD-L1 protein Phenotype Prognosis Receptor, ErbB-2 - analysis Retrospective Studies Triple Negative Breast Neoplasms - chemistry Triple Negative Breast Neoplasms - immunology Triple Negative Breast Neoplasms - pathology Triple Negative Breast Neoplasms - therapy Tumor cells |
| title | Ductal carcinoma in situ of the breast: immune cell composition according to subtype |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ductal%20carcinoma%20in%20situ%20of%20the%20breast:%20immune%20cell%20composition%20according%20to%20subtype&rft.jtitle=Modern%20pathology&rft.au=Agahozo,%20Marie%20Colombe&rft.date=2020-02-01&rft.volume=33&rft.issue=2&rft.spage=196&rft.epage=205&rft.pages=196-205&rft.issn=0893-3952&rft.eissn=1530-0285&rft_id=info:doi/10.1038/s41379-019-0331-8&rft_dat=%3Cproquest_cross%3E2475023446%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2349174693&rft_id=info:pmid/31375764&rfr_iscdi=true |